EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

2′-O-Galloylhyperin Prevents Tissue Remodeling in Thyroid Eye Disease: Prospects as a Thyrotropin Receptor Antagonist

Yan Guo, Boyuan Liu, Weiwei Liang, Yanglei Cheng, Hai Li, Hongyu Guan, Haipeng Xiao iD, Yanbing Li iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae732 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Yan Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China. Hauptthemen laut MEDLINE: Receptors, Thyrotropin, Graves Ophthalmopathy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Key Field Research and Development Program of Guangdong Province, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Thyroid eye disease (TED) is a challenging condition owing to relentless orbital tissue remodeling, with thyrotropin receptor (TSHR) in orbital fibroblasts (OFs) serving as a promising therapeutic target.

Objective

This study seeks to discover potential TSHR inhibitors among US Food and Drug Administration (FDA)-approved drugs and evaluate their effects on TED-OFs.

Methods

Adipose tissues were sourced from the patients with or without TED. Isolated OFs were cultivated in proliferation medium or stimulated for adipogenic/fibrotic differentiation in 2-dimensional/3-dimenstional models, treated with 2′-O-galloylhyperin (2′-O-GH) (0, 5, 20, and 50 μM). Using structure-based virtual screening (SBVS), potential TSHR antagonists were identified. Cellular proliferation was analyzed by 5-ethynyl-2′-deoxyuridine (EdU) incorporation, flow cytometry, and spheroid size. Adipogenesis was determined by Oil Red O staining, Western blot, and immunofluorescence (IF). Fibrosis was assessed using wound–healing assays, Western blot and IF. Cyclic adenosine monophosphate (cAMP), hyaluronan (HA), and cytokine were quantified by enzyme-linked immunosorbent assay.

Results

Herein, the FDA-approved drug 2′-O-GH dose-dependently decreased cAMP production and the subsequent cAMP-response element binding protein (CREB) phosphorylation stimulated by a TSHR-stimulating monoclonal autoantibody M22, which was reversed by a consistently activated mutation of TSHR (L629F). As expected, 2′-O-GH attenuated lipid accumulation in TED-OFs, along with downregulation of key adipogenic markers, and 2′-O-GH ameliorated HA production during adipogenesis. Notably, 2′-O-GH dampened wound closure and fibrotic differentiation of TED-OF stimulated by transforming growth factor beta 1. Correspondingly, proliferation of TED-OFs was halted by 2′-O-GH.

Conclusion

2′-O-GH is promising for prevention of tissue remodeling of TED by exerting inhibitory effects on proliferation, differentiation, and HA deposition by inhibiting TSHR activation, implying its potential therapeutic value for TED.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ThyrotropinGraves OphthalmopathyHumansFibroblastsCell ProliferationAdipogenesisCells, CulturedAdipose TissueFemaleMaleCell DifferentiationMiddle AgedOrbitAdult

Stichwörter der Autor:innen

TSHRantagonistorganoidthyroid eye diseasetissue remodeling

Substanzen

Receptors, ThyrotropinTSHR protein, human

Autor:innen und Institutionen

  • Department of Endocrinology and Diabetes Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.

ORCID-Profile: Haipeng Xiao, Yanbing Li

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Key Field Research and Development Program of Guangdong Province, China
  • Guangdong Basic and Applied Basic Research Foundation

Zitieren

APA

Guo, Y., Liu, B., Liang, W., Cheng, Y., Li, H., Guan, H., Xiao, H., & Li, Y. (2025). 2′-O-Galloylhyperin Prevents Tissue Remodeling in Thyroid Eye Disease: Prospects as a Thyrotropin Receptor Antagonist. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae732

Vancouver

Guo Y, Liu B, Liang W, Cheng Y, Li H, Guan H, et al. 2′-O-Galloylhyperin Prevents Tissue Remodeling in Thyroid Eye Disease: Prospects as a Thyrotropin Receptor Antagonist. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae732

BibTeX
@article{Guo2025,
  author = {Guo, Yan and Liu, Boyuan and Liang, Weiwei and Cheng, Yanglei and Li, Hai and Guan, Hongyu and Xiao, Haipeng and Li, Yanbing},
  title = {2′-O-Galloylhyperin Prevents Tissue Remodeling in Thyroid Eye Disease: Prospects as a Thyrotropin Receptor Antagonist},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae732}
}
Kostenlos starten →